Fallen Angels (1.17.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.
Read Article
Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C)
A nationwide cohort study of patients with multisystem inflammatory syndrome in children (MIS-C), a life-threatening complication of COVID-19 infection, showed that many had severe disease during the acute phase, but most recovered quickly and had a reassuring midterm prognosis.
Read Article
A Modifiable Vascular Risk in SLE
Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece.
https://t.co/zGTGin664D https://t.co/ZO9UlIPNIi
Dr. John Cush @RheumNow( View Tweet )
In #RA, Higher levels of ESR and CRP, but not DAS28, joint counts or global assessments, were significantly associated with the risk of incident ILD in RA. German biologics (RABBIT) registry study compared 139 RA-ILD vs vs 686 controls. https://t.co/IB7aS6IKgT https://t.co/0zN5N7w65l
Dr. John Cush @RheumNow( View Tweet )
Does Colchicine Lower Gout Mortality Risk?
Data from a large UK database finds that gout patients starting urate-lowering therapy (ULT) will benefit from added colchicine prophylaxis by having fewer cardiovascular events.
https://t.co/89BXT5OnVS https://t.co/N4IQzRpcPk
Dr. John Cush @RheumNow( View Tweet )
Alive in 2025 (1.10.2025)
Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com
Read Article
Does Colchicine Lower Gout Mortality Risk?
Data from a large UK database finds that gout patients starting urate-lowering therapy (ULT) will benefit from added colchicine prophylaxis by having fewer cardiovascular events.
Read Article
Data from Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative & Stockholm Psoriasis Cohort (n=769 Pso Pts) finds that PsO severity (PASI) PASI assoc w/ GlycA levels (syst inflammation) & GlycA levels assoc w/ CVD risk (OR=1.23) https://t.co/IwUHILMpnI https://t.co/DnEF3yuTvg
Dr. John Cush @RheumNow( View Tweet )
A Modifiable Vascular Risk in SLE
Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece.
https://t.co/IibXiitVY8 https://t.co/XHBQcdcMAE
Dr. John Cush @RheumNow( View Tweet )
Full read JAMA ILD Review article. ILD= 33% idiopathic (IPF) + 15% hypersensitivity pneumonitis + 25% from CTD.
30% of ILD has cough
Chest CT 91% sensitive, 71% specific
5% decr in FVC/12 mos assoc w/ 2-fold incr in mortality
Rx options nintedanib or pirfenidone, TCZ, MMF, RTX… https://t.co/s5v3XD8QmC https://t.co/iP5yFWkQwb
Dr. John Cush @RheumNow( View Tweet )
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w5G1dEF7Vm https://t.co/cyiQqGBf01 https://t.co/r909qqIh4V
Links:
Dr. John Cush @RheumNow( View Tweet )
A Modifiable Vascular Risk in SLE
MedPage Today
Atherosclerosis progression was more than twice as common in younger people with SLE than in healthy controls in a prospective study from Greece, but the rate difference narrowed substantially with sustained SLE remission and conventional cardiovascular risk factor management.
Read Article
Full read JAMA ILD Review article. ILD= 33% idiopathic (IPF) + 15% hypersensitivity pneumonitis + 25% from CTD.
30% of ILD has cough
Chest CT 91% sensitive, 71% specific
5% decr in FVC/12 mos assoc w/ 2-fold incr in mortality
Rx options nintedanib or pirfenidone, TCZ, MMF, RTX… https://t.co/FKZyNU1s06 https://t.co/w5q0hOesEH
Dr. John Cush @RheumNow( View Tweet )
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w76dY29bwe https://t.co/1LBevDunjH https://t.co/Ix3UxeGUe2
Links:
Dr. John Cush @RheumNow( View Tweet )
Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).
Read Article
Best of 2024: 13 Risk Factors for RA-associated Interstitial Lung Disease
Interstitial lung disease (ILD) is the most widespread and fatal pulmonary complication of rheumatoid arthritis (RA). A recent metanalysis shows the pooled prevalence of RA-ILD was approximately 18.7%.
Read Article
Best of 2024: Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease
https://t.co/Sd3H5Tzhtf https://t.co/guXzL5bc6R
Dr. John Cush @RheumNow( View Tweet )
To Behcet’s or not to Behcet’s?
-Aphtous ulcers have unique features(broad ddx)
-Oral+Genital ulcers=CAP not necessary BD.
-Pathergy test ⬆️specific and not limited to skin!
-Pulmonary arterial aneurysms=almost pathognomonic.
-Do not get confused by HLAs. #ACR24 @RheumNow… https://t.co/3nWgILNVYw
Dr. John Cush @RheumNow( View Tweet )
Bah Humbug Vitamin D (12.20.2024)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
Rheumatoid Arthritis Boosts Risk for Some Types of Heart Failure
Rates of heart failure with preserved ejection fraction (HFpEF) were doubled in patients with rheumatoid arthritis (RA) relative to other people of the same age and sex, researchers found.… https://t.co/t7GRp7c63x https://t.co/Ov6UwGlPko
Dr. John Cush @RheumNow( View Tweet )
Japanese registry study of CV & CA outcomes in #RA. CV (MACE) events = IR 0.49/100 PY.
Cancer= IR 0.78/100PY. MACE risk factors: Male, age≥65, HTN, Renal or cerebrovascular Dz; CA risk w/ Male, age, NSAID, COPD, SIE, CA Hx. https://t.co/uBFbho25La https://t.co/3ClEwCvdDY
Dr. John Cush @RheumNow( View Tweet )
Safety of Acetaminophen in the Elderly
New research, led by experts at the University of Nottingham, has found that repeated doses of paracetamol in people aged 65 and over, can lead to an increased risk of gastrointestinal, cardiovascular and renal complications.… https://t.co/rLchNTh6C8 https://t.co/y2DUx6TQR0
Dr. John Cush @RheumNow( View Tweet )
Are we under-monitoring in scleroderma ILD?
Dr. Janet Pope discusses abstract 0678, Patients with Interstitial Lung Disease Due to Systemic Sclerosis or RA Need Monitoring More Frequently Than Annually, and abstract 0706, Single Center Prospective Cohort of Systemic Sclerosis… https://t.co/GJRWGxUnh3 https://t.co/vtCOXGe4H8
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Are Emulation Trials a Fantasy?
Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?
Read Article
54K Peptic Ulcers Annually (12.13.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Read ArticleRecent Blogs
How would you manage a patient with Overlap (anti-synthetase) syndrome, ILD, polyarthritis and myositis?
Read Post
